Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Stock analysts at HC Wainwright decreased their Q2 2026 EPS estimates for shares of CG Oncology in a note issued to investors on Friday, May 8th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.73) per share for the quarter, down from their prior forecast of ($0.60). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for CG Oncology’s Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($2.42) EPS, FY2028 earnings at ($0.40) EPS, FY2029 earnings at $2.43 EPS and FY2030 earnings at $6.77 EPS.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million.

Other equities research analysts also recently issued reports about the stock. Truist Financial reiterated a “buy” rating and issued a $77.00 target price (up from $75.00) on shares of CG Oncology in a research note on Monday. Piper Sandler raised their target price on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. JPMorgan Chase & Co. raised their target price on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday. Wedbush raised their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CG Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $81.27.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $72.07 on Wednesday. CG Oncology has a 52-week low of $23.32 and a 52-week high of $73.56. The company has a market capitalization of $6.36 billion, a P/E ratio of -30.93 and a beta of 0.41. The company has a 50-day simple moving average of $66.44 and a 200 day simple moving average of $53.45.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. KBC Group NV bought a new position in shares of CG Oncology during the first quarter worth approximately $78,000. Jennison Associates LLC increased its holdings in shares of CG Oncology by 68.5% during the first quarter. Jennison Associates LLC now owns 476,136 shares of the company’s stock worth $32,225,000 after purchasing an additional 193,630 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of CG Oncology by 7.7% during the first quarter. Bank of New York Mellon Corp now owns 167,030 shares of the company’s stock worth $11,305,000 after purchasing an additional 11,874 shares during the period. NFSG Corp bought a new position in shares of CG Oncology during the first quarter worth approximately $34,000. Finally, Sanctuary Advisors LLC bought a new position in shares of CG Oncology during the first quarter worth approximately $422,000. 26.56% of the stock is owned by institutional investors.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 15,600 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director directly owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Key Stories Impacting CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Multiple Wall Street firms raised or reiterated constructive views on CG Oncology, including JPMorgan, RBC, Truist, Wedbush, and HC Wainwright, with price targets ranging from $77 to $100 and several “Buy/Outperform” ratings. CG Oncology (NASDAQ:CGON) Given New $96.00 Price Target at JPMorgan Chase & Co.
• Positive Sentiment: CG Oncology highlighted its presence at the American Urological Association Annual Meeting, where first results from its CORE-008 Phase 2 cohort are set to be presented, reinforcing investor focus on the company’s bladder cancer pipeline. CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
• Neutral Sentiment: HC Wainwright lowered near-term earnings estimates for 2026 and 2027, but kept a $100 price target and “Buy” rating, while lifting longer-term FY2030 earnings expectations.
• Neutral Sentiment: The company also reported mixed first-quarter results recently, which the market appears to be balancing against the improving analyst sentiment and longer-term growth outlook. CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
• Negative Sentiment: HC Wainwright cut EPS estimates for Q2, Q3, Q4 2026, FY2026, FY2027, and FY2028, signaling softer near-term profitability assumptions.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.